The shorter CD33-isoform (D2-CD33), generated as a result of alternate splicing, lacking the ligand binding domain represents a gain of function variant that reduces Alzheimer's disease risk (62). This evidence concerns the gene CD33 and early-onset autosomal dominant Alzheimer disease.